

PAPERS & POSTERS

Preclinical Research

A GLOBAL SERVICE PROVIDER OF PRECLINICAL AND CLINICAL RESEARCH IN OPHTHALMOLOGY

Successful Proof-of-Concept for Topical Delivery of Novel Peptide ALM201 with Potential Usefulness for Treating Neovascular Eye Disorders#2022-246

OBASANMI G (a), NESBIT MA (a), COBICE D (a), MACKAY L (b), MCGIMPSEY S (c), WAPPETT M (d), CRANSTON AN (d), MOORE TCB (a)

Ophthalmol. Sci. 2022; 2, 2, 100150. <https://doi.org/10.1016/j.xops.2022.100150> (collaboration)

(a) BIOMEDICAL SCIENCES RESEARCH INSTITUTE, Ulster University, Coleraine, United Kingdom - (b) Scottish Instrumentation and Research Centre for Advanced Mass Spectrometry (SIRCAMS), University of Edinburgh, Edinburgh, United Kingdom - (c) Mater Infirmorum Hospital, Belfast, United Kingdom - (d) ALMAC DISCOVERY Ltd., Belfast, United Kingdom



New Preservative-Free Formulation for the Enhanced Ocular Bioavailability of Prostaglandin Analogues in Glaucoma#2022-245

ALVISET G (a),(b),(c), CORVIS Y (b), HAMMAD K (d), LEMUT J (e),(f), MAURY M (f), MIGNET N (b), BOUDY V (b),(c)

Pharmaceutics 2022, 14, 453. <https://doi.org/10.3390/pharmaceutics14020453> (collaboration)

(a) UNITHER Développement Bordeaux, Le Haillan, France – (b) CNRS, INSERM, UTCBS, Paris, France - (c) Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France – (d) CNRS, CiTCoM, Paris, France – (e) CMC Expert, Montpellier, France – (f) UNITHER PHARMACEUTICALS, Paris, France



A comparative pharmacokinetics study of 3 Latanoprost eyedrops solutions containing various excipients in an animal model#2022-244

REBIKA H (a),(c), CHAUCHAT L (a), AMAR T (b), VIAUD-QUENTRIC K (b), GUERIN C (a)

ARVO meeting 2022; Denver, CO - USA. Abstract No. 4166 – F0158

Invest. Ophthalmol. Vis. Sci. 2022;63(7):4166 – F0158.

(a) HORUS PHARMA, Saint Laurent du Var, France – (b) IRIS PHARMA, La Gaude, France – (c) Centre Hospitalier Universitaire de Clermont-Ferrand, France



Comparison of two experimental mouse dry eye models through inflammatory gene set enrichment analysis based on a multiplexed transcriptomic approach#2021-243

KESSAL K (a),(b),(c), DAULL P (d), CIMBOLINI N (e), FERAILLE L (e), GRILLO S (e), DOCQUIER M (f), BAUDOUIN C (a),(b),(c),(g), BRIGNOLE-BAUDOUIN F (a),(b),(c),(h), GARRIGUE JS (d)

Int. J. Mol. Sci. 2021; 22, 10770. <https://doi.org/10.3390/ijms221910770>

(a) INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU ForeSight, Sorbonne Université UM80, Paris, France - (b) Centre Hospitalier National d'Ophthalmologie des Quinze-Vingts, INSERM-DGOS CIC1423, IHU FOReSight, Paris, France - (c) Centre Hospitalier National d'Ophthalmologie des Quinze-Vingts, Paris, France - (d) SANTEN SAS, Evry, France - (e) IRIS PHARMA, La Gaude, France - (f) iGE3 Genomics Platform, University of Geneva, Geneva, Switzerland - (g) Ambroise Paré, APHP, Department of Ophthalmology, University Paris Saclay, Boulogne, France - (h) Faculté de Pharmacie, Université de Paris, Paris, France



Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye#2021-240

SANTONOCITO M (a), ZAPPULLA C (a), VIOLA S (a), LA ROSA LR (a), SOLFATO E (a), ABBATE I (a), TARALLO V (b), APICELLA I (b), PLATANIA CBM (c), MAUGERI G (c), D'AGATA V (c), BUCOLO C (c), DE FALCO S (b), MAZZONE MG (a), GIULIANO F (a)

Int. J. Mol. Sci. 2021; 22, 4404. <https://doi.org/10.3390/ijms22094404> (collaboration)

(a) SIFI S.p.A., Catania, Italy - (b) Institute of Genetics and Biophysics, CNR, Napoli, Italy - (c) Department of Biomedical and Biotechnological Sciences, University of Catania, Italy



Review of Preclinical Outcomes of a Topical Cationic Emulsion of Cyclosporine A for the Treatment of Ocular Surface Diseases#2021-239

DAULL P (a), BAUDOUIN C (b), LIANG H (c), FERAILLE L (d), BARABINO S (e), GARRIGUE JS (a)

Ocul. Immunol. Inflamm. 2021; Aug 4; 1-11. doi: 10.1080/09273948.2021.1957124

(a) SANTEN SAS, Evry, France - (b) CHNO des Quinze-Vingts, IHU FOReSIGHT, INSERM-DGOS CIC 1423, Paris, France - (c) Sorbonne Universités, INSERM, CNRS, Institut de la Vision, Paris, France - (d) IRIS PHARMA, La Gaude, France - (e) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy



MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment#2021-238

ENTCHEV E (a), ANTONELLI S (b), MAURO V (b), CIMBOLINI N (b), JANTZEN I (a), ROUSSEY A (a), GERMAIN JM (a), ZHANG H (c), LUCCARRINI JM (a), LACOMBE O (a), YOUNG S (c)(d), FERAILLE L (b), TALLANDIER M (a)

Mol. Genet. Metab. 2021; doi: 10.1016/j.ymgme.2021.07.008 (pre-print on July 25, 2021)

(a) INVENTIVA PHARMA, Daix, France - (b) IRIS PHARMA, La Gaude, France - (c) DUKE UNIVERSITY HEALTH SYSTEM BIOCHEMICAL GENETICS LAB, Durham, NC, USA - (d) DUKE SCHOOL OF MEDICINE, Durham, NC, USA



A rare natural lipid induces neuroglobin expression to prevent amyloid oligomers toxicity and retinal neurodegeneration#2021-237

OAMEN HP (a), ROMERO N (a), KNUCKLES P (b), SAARIKANGAS J (c), DONG Y (d), CAUDRON F (a)

doi: 10.1101/2021.06.23.449608 (pre-print on June 23, 2021) (collaboration)

(a) SCHOOL OF BIOLOGICAL SCIENCES, London, UK - (b) FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland - (c) HELSINKI INSTITUTE OF LIFE SCIENCE, Helsinki, Finland; UNIVERSITY OF HELSINKI, Finland - (d) SUNREGEN HEALTHCARE AG, Reinach, Switzerland

Ocular surface response of two preservative-free cyclosporine A emulsion eye drops in a mouse model of dry eye#2021-236

DAULL P (a), NAGANO T (b), **GROS E** (c), **FERAILLE L** (c), BARABINO S (d), GARRIGUE JS (a)

Curr. Eye Res. 2021. doi: 10.1080/02713683.2021.1878228

(a) SANTEN SAS, Evry, France - (b) SANTEN Pharmaceutical Co., Ltd., Osaka, Japan - (c) IRIS PHARMA, La Gaude, France - (d) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy



DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously#2021-235

BECKMANN R (a), JENSEN K (a), FENN S (a) et al.

Nature 2021; 12, 708. doi: 10.1038/s41467-021-20949-3 (collaboration)

(a) ROCHE PHARMA Research and Early Development, Penzberg, Germany



Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/ Δ FosB-VCAM-1 axis#2020-231

Y LI (a), A ALHENDI (a), MC YEH (a), M ELAHY (a), F SANTIAGO (a), N DESHPANDE (b), B WU (a), E CHAN (a), S INAM (a), L PRADO-LOURENCO (a), J MARCHAND (c), R JOYCE (c), L WILKINSON-WHITE (d), M RAFTERY (e), M ZHU (f,g,h), S ADAMSON (h), **F BARNAT** (i), **K VIAUD-QUENTRIC** (i), J SOCKLER (j), J MACKAY (k), A CHANG (g,h,l), P MITCHELL (m), S MARCUCCIO (c,n), L KHACHIGIAN (a)

Sci. Adv. 2020; 6 : eaaz7815 DOI: 10.1126/sciadv.aaz7815

(a) Vascular Biology and Translational Research, UNIVERSITY OF NEW SOUTH WALES, Sydney, Australia (b) Systems Biology Initiative, UNIVERSITY OF NEW SOUTH WALES, Sydney, Australia – (c) ADVANCED MOLECULAR TECHNOLOGIES Pty Ltd, Scoresby, Australia – (d) Sydney Analytical Core Facility, UNIVERSITY OF SYDNEY, Australia – (e) Bioanalytical Mass Spectrometry Facility, UNIVERSITY OF NEW SOUTH WALES, Sydney, Australia – (f) New South Wales Tissue Bank, Kogarah, Australia – (g) SAVE SIGHT INSTITUTE, University of Sydney, Australia – (h) GREENLIGHT CLINICAL Pty. Ltd., Woolloomooloo, Australia – (i) IRIS PHARMA, La Gaude, France – (j) DATAPHARM AUSTRALIA Pty. Ltd., Drummoyne, Australia – (k) School of Life and Environmental Sciences, UNIVERSITY OF SYDNEY, Australia – (l) SYDNEY EYE HOSPITAL, Australia – (m) Centre for Vision Research, WESTMEAD INSTITUTE OF MEDICAL RESEARCH, Westmead, Australia – (n) LA TROBE INSTITUTE FOR MOLECULAR SCIENCE, Melbourne, Australia



SBC003 demonstrates neuroprotective effects in a murine model of N-nitroso-N-methylurea (NMU) induced photoreceptor degeneration#2020-230

DONG Y (a), HARKIN K (b), **FERAILLE L** (c), CHEN M (b), XU H (b)

Invest. Ophthalmol. Vis. Sci. 2020; 61(7):2475.

(a) SUNREGEN HEALTHCARE AG, Allschwil, Switzerland - (b) QUEEN'S UNIVERSITY BELFAST, United Kingdom - (c) IRIS PHARMA, La Gaude, France



The uni-nephrectomized and salt-loaded SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy#2020-229

SHINOHARA M (a), BRIAND F (b), **ANTONELLI S** (c), **MAURO V** (c), **CIMBOLINI N** (c), BROUSSEAU E (b), OHTA T (d), MIYAJIMA K (e), KAGEYAMA Y (a), **FERAILLE L** (c), SULPICE T (b)

Japanese Society of Toxicologic Pathology meeting 2020; Tokuo, JAPAN

(a) CLEA Japan Inc., Tokyo, Japan - (b) PHYSIOGENEX, Labège, France - (c) IRIS PHARMA, La Gaude, France - (d) Kyoto University, Kyoto, Japan - (e) Tokyo University of Agriculture, Tokyo, Japan

Modulation of inflammation-related genes in the cornea of a mouse model of dry eye upon treatment with cyclosporine eye drops#2019-222

DAULL P (a), BARABINO S (b), **FERAILLE L** (c), KESSAL K (d), DOCQUIER (e), PARSADANIANTZ S (d), BAUDOUIN C (d,f), GARRIGUE JS (a)

Curr. Eye Res. 2019; Jan 21:1-10. doi: 10.1080/02713683.2018.1563197

(a) SANTEN SAS, Evry, France - (b) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy - (c) IRIS PHARMA, La Gaude, France - (d) INSTITUT DE LA VISION, Paris, France - (e) iGE3 Genomics Platform, University of Geneva, Switzerland - (f) Quinze-Vingts National Ophthalmology Hospital, Paris, France



Chronic model of uveitis in rabbit - Efficacy of triamcinolone acetonide#2019-221

QUENTRIC Y (a), **ANTONELLI S** (a), **MAURO V** (a), **CIMBOLINI N** (a), **FERAILLE L** (a), **ELENA PP** (a)

ARVO meeting 2019; Vancouver - CANADA. Abstract No. 800 - B0278

(a) IRIS PHARMA, La Gaude, France



Efficacy of preservative-free cyclosporine emulsion eye drops in a mouse model of dry eye

DAULL P (a), NAGANO T (b), OKADA S (b), **GROS E** (c), **FERAILLE L** (c), GARRIGUE JS (a)

ARVO meeting 2019; Vancouver - CANADA. Abstract No. 292 - B0431

(a) SANTEN SAS, Evry, France - (b) SANTEN Ltd., Osaka, Japan - (c) IRIS PHARMA, La Gaude, France

.....#2019-220



Dry Eye: efficacy evaluation of two synthetic peptides from chondrocyte derived extracellular matrix (CDEM) in comparison to lifitegrast, cyclosporine A, diquafosol sodium and sodium hyaluronate in a murine model of dry eye

BAIK T (a), CHOI J (a), MIN K (a), **FERAILLE L** (b), **RAYMOND E** (b), **ELENA PP** (b)

ARVO meeting 2019; Vancouver - CANADA. Abstract No. 291 - B0430

(a) YUYU PHARMA, Seoul, The Republic of Korea - (b) IRIS PHARMA, La Gaude, France

.....#2019-219



Comparison of inflammatory gene networks in dry eye between human and mouse

KESSAL K (a,b), DAULL P (c), **FERAILLE L** (d), **CIMBOLINI N** (d), LIANG H (a,b), DOCQUIER (e), BARABINO S (f), MELIK PARSADANIANTZ S (a), GARRIGUE JS (c), BAUDOUIN C (a,b), BAUDOUIN F (a,b)

ARVO meeting 2019; Vancouver - CANADA. Abstract No. 274 - B0413

(a) INSTITUT DE LA VISION, Paris, France - (b) Quinze-Vingts National Ophthalmology Hospital, Paris, France - (c) SANTEN SAS, Evry, France - (d) IRIS PHARMA, La Gaude, France - (e) iGE3 Genomics Platform, University of Geneva, Switzerland - (f) CLINICA OCULISTICA, Genova, Italy

.....#2019-218



Topical Administration of Spironolactone-Loaded Nanomicelles Prevents Glucocorticoid-Induced Delayed Corneal Wound Healing in Rabbits

DAHMANA N (a), MUGNIER T (b), GABRIEL D (b), KALTSATOS V (c), BERTAIM T (c), BEHAR-COHEN F (d,e), GURNY R (a,b), KALIA Y (a) (collaboration)

Mol Pharm. 2018 Mar 5;15(3):1192-1202. doi: 10.1021/acs.molpharmaceut.7b01028

(a) University of Geneva & University of Lausanne, Geneva, Switzerland - (b) APIDEL SA, Geneva, Switzerland - (c) CEVA Santé Animal, Libourne, France - (d) Fondation Asile des Aveugles, Hôpital Ophtalmique Jules-Gonin, Lausanne, Switzerland - (e) INSERM, UMRS 872 Team 17, Paris, France

.....#2018-241



Safety and tolerability of overdosed artificial tears by abraded rabbit corneas

DAULL P (a), **RAYMOND E** (b), **FERAILLE L** (b), GARRIGUE JS (a)

J. Ocul. Pharmacol. Ther. 2018; DOI: 10.1089/jop.2018.0040

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France

.....#2018-215



The uni-nephrectomized SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy over 10 weeks

BRIAND F (a), **ANTONELLI S** (b), **MAURO V** (b), **CIMBOLINI N** (b), SHINOHARA M (c), BROUSSEAU E (a), OHTA T (d), KAGEYAMA Y (c), **FERAILLE L** (b), SULPICE T (a)

ARVO meeting 2018; Hawaii - USA. Abstract No. 3573 - A0190

(a) PHYSIOGENEX, Labege, France - (b) IRIS PHARMA, La Gaude, France - (c) CLEA Japan Inc., Tokyo, Japan - (d) JAPAN TOBACCO Inc., Osaka, Japan

.....#2018-214



Ocular tolerance in rabbits after intracameral administration of a fixed combination of tropicamide, phenylephrine, and lidocaine with and without rinsing

NUIJTS R (a), MENCUCCI R (b), **VIAUD-QUENTRIC K** (c), **ELENA PP** (c), OLMIERE C (d), BEHNDIG A (e)

J. Cataract Refr. Surg. 2017; 43: 673-679. DOI: 10.1016/j.jcrs.2017.03.025

(a) Maastricht Universitair Medisch Centrum, the Netherlands - (b) University of Florence, Italy - (c) IRIS PHARMA, La Gaude, France - (d) LABORATOIRES THEA, Clermont-Ferrand, France - (e) Umeå University, Sweden

.....#2017-227



Exploratory ocular surface distribution studies of azithromycin formulations based on semifluorinated alkanes

FISCHER K (a), GRILLENBERGER R (a), **AMAR T** (b), KRÖSSER S (a)

EVER meeting 2017; Nice, France. Acta Ophthalmologica. DOI: 10.1111/j.1755-3768.2017.0S029

(a) NOVALIQ GmbH, 69120 Heidelberg, Germany - (b) IRIS PHARMA, La Gaude, France

.....#2017-213



Oral administration of the 11 β -hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study

SCHWAB D (a), STURM C (a), PORTRON A (a), FUERST-RECKTENWALD S (b), HAINZL D (c), JORDAN P (d), STEWART W (e), TEPEDINO M (f), DUBINER H (g)

BMJ Open Opth 2017;1:e000063. DOI: 10.1136/bmjophth-2016-000063 (collaboration)

(a) ROCHE INNOVATION CENTER, Clinical Pharmacology, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (b) ROCHE INNOVATION CENTER, Translational Medicine, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (c) ROCHE INNOVATION CENTER, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Basel, Switzerland (d) Department of Biometrics, Product development, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (e) PRN Pharmaceutical Research Network, LLC, Cheyenne, Wyoming, USA - (f) Cornerstone Eye Care, Division of Health Care, High Point, North Carolina, USA - (g) Eye Care Centers Management, Inc., Clayton Eye Center, Morrow, Georgia, USA

.....#2017-212



Transform your microscope into an ultramicroscope for 3D imaging of cleared organs

#2017-211

GESSION M (a), **KECHAD M** (b), MAUCLERT N (c), GIRARD P (c), ROUSSEL A (c), PIERRE O (d), GROSJEAN I (e), BRAU F (f)
Focus on Microscopy meeting 2017; Bordeaux - France. Poster No P2-A/26

(a) CNRS, INSERM, Institut Biologie Valrose, Nice, France - (b) IRIS PHARMA, La Gaude, France - (c) OCA, Service de Mécanique Mutualisé, France - (d) IINRA, Institut Sophia Agrobiotech, Biot, France - (e) INSERM, Institut de Recherche sur le Cancer et le Vieillessement, Nice, France - (f) CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France



Comparative efficacy of preservative-free anti-inflammatory eye drops in a mouse model of dry eye

#2017-210

GARRIGUE JS (a), **CIMBOLINI N** (b), KESSAL K (c), **GROS E** (b), **MAURO V** (b), BARABINO S (d), BAUDOUIN C (c), DAULL P (a)
ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 800. doi:

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) INSTITUT DE LA VISION, Paris, France - (d) CLINICA OCULISTICA, Genoa, Italy



Conditional self-knockout of otx2 mice: a new model for late-onset neuronal degeneration

#2017-209

ELENA PP (a), **ANTONELLI S** (a), **MAURO V** (a), **CIMBOLINI N** (a), LAMONERIE T (b), **FERAILLE L** (a)

ARVO meeting 2017; Baltimore - USA. ARVO e-abstract No. 4532 - Poster B0187
(a) IRIS PHARMA, La Gaude, France - (b) UNIVERSITE DE NICE, Nice, France



Corneal transcriptome changes in a mouse model of dry eye

#2017-208

DAULL P (a), **FERAILLE L** (b), KESSAL K (c), **ELENA PP** (b), BARABINO S (d), BAUDOUIN C (c), GARRIGUE JS (a)

ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 797. doi:
(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) INSTITUT DE LA VISION, Paris, France - (d) CLINICA OCULISTICA, Genoa, Italy



Safety evaluation of cationic emulsions following refractive surgery procedures

#2017-207

QUENTRIC Y (a), DAULL P (b), **GROS E** (a), **ANTONELLI S** (a), **MAURO V** (a), **FERAILLE L** (a), GARRIGUE JS (b)

ARVO meeting 2017; Baltimore - USA. ARVO e-abstract No. 5297 - Poster B0250
(a) IRIS PHARMA, La Gaude, France - (b) NOVAGALI Innovation Center, SANTEN SAS, Evry, France



Binding to ocular albumin as a half-life extension. Principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies

#2017-206

FUCHS H (a), IGNEY F (a)

J. Ocul. Pharmacol. Ther. 2017; DOI: 10.1089/jop.2016.0083 (collaboration)
(a) BOEHRINGER INGELHEIM PHARMA GmbH & Co. KG, Biberach an der Riss, Germany



Efficacy of a preservative-free cationic emulsion vehicle eye drop in a mouse model of dry eye

#2016-223

QUENTRIC Y (a), DAULL P (b), **FERAILLE L** (a), **ELENA PP** (a), GARRIGUE JS (b)

ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57: 422. doi:
(a) IRIS PHARMA, La Gaude, France - (b) NOVAGALI Innovation Center, SANTEN SAS, Evry, France



Norbixin protects retinal pigmented epithelium cells and photoreceptors against A2E-mediated phototoxicity in vitro and in vivo

#2016-205

FONTAINE V (a), MONTEIRO E (a), BRAZHNIKOVA E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), **FERAILLE L** (c), **ELENA PP** (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b)

PLOS ONE 11(12): e0167793. doi: 10.1371/journal.pone.0167793
(a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France



Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye

#2016-204

DAULL P (a), **FERAILLE L** (b), BARABINO S (c), **CIMBOLINI N** (b), **GRILLO-ANTONELLI S** (b), **MAURO V** (b), GARRIGUE JS (a)

Exp. Eye Res. 2016; Oct 21; 153:159-164
(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy



Ocular tolerance in rabbits of intracameral administration of MYDRANE, a fixed combination of tropicamide, phenylephrine, and lidocaine for cataract surgery

#2016-202

OLMIERE C (a), **VIAUD K** (b)

EVER meeting 2016; Nice - France
(a) LABORATOIRES THEA, Clermont-Ferrand, France - (b) IRIS PHARMA, Nice, France



SMA+ perivascular cells evaluation in VEGF induced blood-retinal barrier breakdown in rabbit model

#2016-201

ELENA PP (a), **MAURO V** (a), **GRILLO-ANTONELLI S** (a), **CIMBOLINI N** (a), **VIAUD-QUENTRIC K** (a), **FERAILLE L** (a)

EVER meeting 2016; Nice - France
(a) IRIS PHARMA, La Gaude, France



Pre-clinical in vivo (animal) testing of ocular formulations and drug delivery systems

#2016-200

ELENA PP (a)

Ocular Drug Delivery; Berlin - Germany. Oral communication

(a) IRIS PHARMA, La Gaude, France

Comparative efficacy of cyclosporine A eye drop formulations in a mouse model of dry eye

#2016-199

GARRIGUE JS (a), DAULL P (a), FERAILLE L (b), BARABINO S (c)

ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57(12): 421. doi:

(a) SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy



BIO201: a new drug candidate for the treatment of dry AMD

#2016-198

FONTAINE V (a), BRAZHNIKOVA E (a), MONTEIRO E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b)

ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57: 1119. doi:

(a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France



Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient / Tolérance à long terme d'un collyre sans conservateur contenant comme excipient du macrogol hydroxystearate

#2016-197

VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), ELENA PP (a)

J. Fr. Ophthalmol. 2016; Feb; 39(2): 156-63; Doi : 10.1016/j.jfo.2015.09.011

(a) IRIS PHARMA, Nice, France



Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping

#2016-196

DAULL P (a), FERAILLE L (b), ELENA PP (b), GARRIGUE JS (a)

J. Ocul. Pharmacol. Ther. 2016; DOI: 10.1089/jop.2015.0054

(a) SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France



HL036337 ophthalmic solution: topical TNF blocker for dry eye disease

#2015-216

Protein and AntiboPEGs meeting 2015; Boston, MA (collaboration)

HanAll BioPharma Co., Ltd, Seoul, Korea



Cationic emulsion of cyclosporine for the management of ocular surface inflammation: a preclinical evaluation

#2015-195

DAULL P (a), FERAILLE L (b), AMRANE M (a), ELENA PP (b), GARRIGUE JS (a)

IOIS meeting 2015; San Francisco - USA

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France



Comparison of CKC- and BAK-cationic emulsions in a rat model of corneal wound healing

#2015-194

DAULL P (a), FERAILLE L (b), ELENA PP (b), GARRIGUE JS (a)

EVER meeting 2015; Nice - France. Poster T034

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France



Evaluation of a cyclosporine A ophthalmic ointment in an experimental mouse model of dry eye

#2015-193

CIMBOLINI N (a), ANTONELLI S (a), MAURO V (a), FERAILLE L (a), ELENA PP (a)

EVER meeting 2015; Nice - France. Poster T031

(a) IRIS PHARMA, La Gaude, France



Efficacy evaluation of a cationic emulsion of cyclosporine in a mouse model of dry eye

#2015-192

DAULL P (a), FERAILLE L (b), BARABINO S (c), GARRIGUE JS (a)

ARVO meeting 2015; Denver, CO - USA. ARVO e-abstract No. 4468 - Poster A0094

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genova, Italy



Effects of the multi-kinase inhibitor regorafenib on ocular neovascularization

#2015-191

KLAR J (d), BOETTGER M (a,d), FREUNDLIEB J (c), KELDENICH J (c), ELENA PP (b), VON DEGENFELD G (d)

ARVO meeting 2015; DENVER, CO - USA. ARVO e-abstract No. 243 - Poster C0118

(a) Clinical Sciences Experimental Medicine, BAYER PHARMA AG, Wuppertal, Germany - (b) IRIS PHARMA, Nice, France - (c) BAYER PHARMA AG, Wuppertal, Germany - (d) Ophthalmology, BAYER PHARMA AG, Wuppertal, Germany



Comparison of the effect of dexamethasone and prednisolone acetate in a rat model of glucocorticoid-induced ocular hypertension following topical delivery

#2015-190

ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), BOUZIN M (a), FERAILLE L (a), VIAUD-QUENTRIC K (a), NICOLAS MF (b), LAURENT S (c), BLOT C (c)

ARVO meeting 2015; DENVER, CO - USA. ARVO e-abstract No. 2001 - Poster D0244

(a) IRIS PHARMA, Nice, France - (b) SANOFI R&D - LGCR, Vitry-sur-Seine, France (c) SANOFI R&D - Ophthalmology Unit, Paris, France



In vivo ocular tolerance of a new preservative-free eye drop formulation in rabbits**QUENTRIC Y (a), VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), ELENA PP (a)**

ARVO meeting 2015; Denver, CO - USA. ARVO e-abstract No. 802 - Poster D0264

(a) IRIS PHARMA, Nice, France

.....#2015-189

**Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation**

Invest. Ophthalmol. Vis. Sci 2014; 55: 2859. doi: (collaboration)

TO-BBB TECHNOLOGIES BV, Leiden, Netherlands

.....#2014-224

**The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye****BARABINO S (a), ANTONELLI S (b), CIMBOLINI N (b), MAURO V (b), BOUZIN M (b)**

Invest. Ophthalmol. Vis. Sci. 2014; 55:6499-6504 doi:10.1167/iovs.14-14548

(a) CLINICA OCULISTICA, GENOCA, ITALY - (b) IRIS PHARMA, Nice, France

.....#2014-188

**Two simple animal models of intraocular pressure elevation for testing therapeutic drugs in glaucoma****GRILLO-ANTONELLI S (a), CIMBOLINI N (a), FERAILLE L (a), ELENA PP (a)**

EVER meeting 2014; Nice - France. Poster T017

(a) IRIS PHARMA, Nice, France

.....#2014-187

**Regulatory issues related to preclinical animal research****ELENA PP (a)**

ARVO meeting 2014; Orlando, FL - USA. Oral communication

(a) IRIS PHARMA, Nice, France

.....#2014-186

**Plasma and ocular pharmacokinetic study comparing 3 µL micro-drop to typical 40 µL drop volume of timolol 0.5% in pigmented rabbits**VAN DER HEIDEN H (a,b), **AMAR T (c)**, LICHTENAUEUR W (a)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 453 - Poster D0072

(a) MU-DROP, Apeldoorn, Netherlands - (b) ZAMB, Hospital Pharmacy, Tilburg, Netherlands - (c) IRIS PHARMA, Nice, France

.....#2014-185

**Ocular pharmacokinetic study comparing ramipril and ramiprilat formulations administered orally or topically in pigmented rabbits****QUENTRIC Y (a), AMAR T (a), BARRE N (a), FERAILLE L (a), REKIK R (b)**

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 2360 - Poster B0036

IRIS PHARMA, Nice, France - (b) OPHTHALMOLOGY CLINIC, Tunis, Tunisia

.....#2014-184

**Safety and tolerability of drugs within the suprachoroidal space in albino rabbits**PATEL S (a), VERHOEVEN R (a), BURKE B (a), **CACCIAMANI F (b)**, **VIAUD-QUENTRIC K (b)**, EDELHAUSER H (c,a)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 4886 - Poster C0082

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France - (c) EMORY UNIV EYE CENTER, Atlanta, GA, USA

.....#2014-183

**Biocompatibility of MedinGel biodegradable drug delivery system in the eye**SPIS M (a), **FERAILLE L (b)**, **ANTONELLI S (b)**, **CIMBOLINI N (b)**, **ELENA PP (b)**, GAUDRIAULT G (a), PETIT A (a)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 5273 - Poster C0069

(a) MEDINCELL, Jacou, France - (b) IRIS PHARMA, Nice, France

.....#2014-182

**Dry eye: two experimental rodent models for drug development****CIMBOLINI N (a)**, **ANTONELLI S (a)**, BARABINO S (b), **FERAILLE L (a)**, **MARGARON P (a)**, **ELENA PP (a)**

TFOS meeting 2013; Taormina - Sicily - Italy

(a) IRIS PHARMA, Nice, France - (b) CLINICA OCULISTICA, Genova, Italy

.....#2013-181

**Effects of cyclosporine in an experimental rat model of dry eye****CIMBOLINI N (a)**, **ANTONELLI S (a)**, **FERAILLE L (a)**, **MARGARON P (a)**, **ELENA PP (a)**

EVER meeting 2013; Nice - France. Poster S008

(a) IRIS PHARMA, Nice, France

.....#2013-180

**Impact of the routes of administration on the effects of cyclosporine in an experimental rat model of dry eye****CIMBOLINI N (a)**, **GRILLO-ANTONELLI S (a)**, **FERAILLE L (a)**, **MARGARON P (a)**, **ELENA PP (a)**

ISOPT meeting 2013; Paris - France

(a) IRIS PHARMA, Nice, France

.....#2013-179

**CLS1001 suprachoroidal injectable suspension of triamcinolone acetonide is well tolerated in the albino rabbit**

VERHOEVEN R (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b), PATEL S (a)

American College of toxicology 2013 San Antonio, Texas - USA. Poster P505

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France

.....#2013-178

Suprachoroidal microinjection of triamcinolone acetonide is well tolerated in the albino rabbit

VERHOEVEN R (a), PATEL S (a), **VIAUD-QUENTRIC K** (b), **CACCIAMANI F** (b), **AMAR T** (b), YERXA B (a)
ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 119 - Poster C0124
(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France

#2013-177



Comparison of two rodent models of dry eye induced by scopolamine

ELENA PP (a), **CIMBOLINI N** (a), **ANTONELLI S** (a), **FERAILLE L** (a), BARABINO S (b), **MARGARON P** (a)
ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 6002 - Poster A0065
(a) IRIS PHARMA, Nice, France - (b) CLINICA OCULISTICA, Genova, Italy

#2013-176



Assessment of a new device for conjunctival impression

ROY P (a), **CIMBOLINI N** (b), **ANTONELLI S** (b), **FERAILLE L** (b), **ELENA PP** (b), BAUDOUIN C (c)
MCLOSA meeting 2012; London - England
(a) OPIA Technologies, Paris, France - (b) IRIS PHARMA, Nice, France - (c) Ophthalmology, Quinze-Vingts Hospital, Paris, France

#2012-174



Protection of blue light induced retinal degeneration by the free radical scavenger phenyl-N-tert-butyl nitron and a serotonin receptor 5-HT_{1a} agonist in rats

GRILLO-ANTONELLI S (a), **CIMBOLINI N** (a), DUBOS H (a), **FERAILLE L** (a), **MARGARON P** (a), **ELENA PP** (a)
EVER meeting 2012; Nice - France. Poster S063
(a) IRIS PHARMA, Nice, France

#2012-173



Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping

DAULL P (a), **FERAILLE L** (b), **ELENA PP** (b), BAUDOUIN C (c), GARRIGUE JS (a)
EVER meeting 2012; Nice - France. Poster T036
(a) NOVAGALI PHARMA SA, Evry, France - (b) IRIS PHARMA, Nice, France - (c) INSTITUT DE LA VISION, Paris, France

#2012-172



Ocular surface effects of antiglaucoma combination therapies in a rat model of corneal scraping

DAULL P (a), GARRIGUE JS (a), **FERAILLE L** (b), BAUDOUIN C (c), **ELENA PP** (b)
EVER meeting 2012; Nice - France. Poster T037
(a) NOVAGALI PHARMA SA, Evry, France - (b) IRIS PHARMA, Nice, France - (c) INSTITUT DE LA VISION, Paris, France

#2012-171



Multiple topical administrations of Ramipril enhance retinal ganglion cell survival after transient retinal ischemia-reperfusion in rats

ELENA PP (a), **VIAUD-QUENTRIC K** (a), CHARFEDDINE R (b), REKIK R (c)
EVER meeting 2012; Nice - France. Poster F029
(a) IRIS PHARMA, Nice, France - (b) UNIMED, Sousse, Tunisie - (c) Ophthalmology Clinic, Tunis, Tunisia

#2012-170



Augmentation of the ocular penetration of dexamethasone with β -blocker and α -agonist co-administration

ELENA PP (a), **SENSEBY F** (a), **BERMON F** (a), CHARFEDDINE R (b), REKIK R (c)
EVER meeting 2012; Nice - France. Poster F107
(a) IRIS PHARMA, Nice, France - (b) UNIMED, Sousse, Tunisie - (c) Ophthalmology Clinic, Tunis, Tunisia

#2012-169



Anti-inflammatory effects of glucocorticoids on endotoxin-induced uveitis in rats: effects of the mode of administration

ELENA PP (a), **CIMBOLINI N** (a), **ANTONELLI S** (a), DUBOS H (a), **FERAILLE L** (a), **MARGARON P** (a)
ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6285 - Poster D 1145
(a) IRIS PHARMA, Nice, France

#2012-168



Assessment of intra-ocular pressure lowering effect of novel gel formulations of Latanoprost and Timolol in nonhuman primates following topical delivery

GOODY RJ (a), WHITTAKER S (a), HENRY S (a), BROOKES R (a), STRUHARIK M (a), **BERMON F** (b), **MARGARON P** (b), **POLZER H** (c), LAWRENCE MS (a)
ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1968 - Poster D 812
(a) RXGen, Hamden, CT - (b) IRIS PHARMA, Nice, France - (c) MEDPROJECT PHARMA, Bayern, Germany

#2012-167



Assessment of a new device for conjunctival impression

ROY P (a), **CIMBOLINI N** (b), **ANTONELLI S** (b), **FERAILLE L** (b), **ELENA PP** (b), BAUDOUIN C (c)
ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1868 - Poster A 331
(a) OPIA Technologies, Paris, France - (b) IRIS PHARMA, Nice, France - (c) Ophthalmology Quinze-Vingts Hospital, Paris, France

#2012-166



Assessment of a new device for conjunctival impression

ROY P (a), **CIMBOLINI N** (b), **ANTONELLI S** (b), **FERAILLE L** (b), **ELENA PP** (b)
ISOPT meeting 2011; Vienna, Austria (oral presentation)
(a) OPIA Technologies, Paris, France - (b) IRIS PHARMA, Nice, France

#2011-165

Evaluation of membrane material for impression cytology

ROY P (a), **CIMBOLINI N** (b), **FERAILLE L** (b), **KECHAD M** (b), **ELENA PP** (b)
ARVO meeting 2011; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1937 - Poster D 918
(a) OPIA Technologies, Paris, France - (b) IRIS PHARMA, Nice, France

#2011-161



Ocular distribution and spectrum of activity of a fully human anti-herpes simplex virus IgG Fab fragment, following topical application

BERDUGO-POLAK M (a,b), LARSEN IV (c), ABADIE C (d), KOWALCZUK L (a,b), TOUCHARD E (a,b), NELSON JD (e), **ELENA PP** (f), BRANDT CR (c), BEHAR-COHEN F (a,b,g), COMBETTE JM (d)
ARVO meeting 2010; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1991/ D1028
(a) INSERM UMRS 872, Paris, France - (b) Pierre et Marie Curie University, Paris, France - (c) University of Wisconsin School of Medicine and Public Health, Madison, WI - (d) ribOvax Biotechnologies, Petit-Lancy, Switzerland - (e) Calmune Corporation, San Diego, CA - (f) IRIS PHARMA, La Gaude, France - (g) Hotel-Dieu University Hospital, Paris, France

#2010-160



Designing dendrimers for ocular delivery

SPATARO G (a,b), MALECAZE F (c), TURRIN CO (a,b), SOLER V (c), DUHAYON C(a,b), **ELENA PP** (d), MAJORAL JP (a,b), CAMINADE AM (a,b)
Eur. J. Med. Chem. 2010; 45: 326-334
(a) CNRS, Laboratoire de Chimie de Coordination, Toulouse, France - (b) Université de Toulouse, Toulouse, France - (c) Hôpital Purpan, Toulouse, France - (d) IRIS PHARMA, Nice, France

#2010-157



Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation

AKPEK EK (a), VITTITOW J (b), VERHOEVEN RS (b), BRUBAKER K (b), **AMAR T** (c), POWELL KD (d), BOYER JL (b), CREAN C (b)
J. Ocul. Pharmacol. Ther. 2009; 25: 433-439
(a) THE WILMER EYE INSTITUTE, Johns Hopkins Hospital, Baltimore, USA - (b) INSPIRE Pharmaceuticals, Durham, USA - (c) IRIS PHARMA, Nice, France - (d) ENTHALPY ANALYTICAL, Durham, USA

#2009-156



Corneal effect of topical diclofenac co-administration with aminoside and steroid in rabbits

CAILLAUD T (a), **VIAUD K** (a), **ELENA PP** (a)
ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1957
(a) IRIS PHARMA, Nice, France

#2009-154



Snapshot test for investigating gels of anti-glaucoma compounds as topical formulations

ELENA PP (a), **POLLIN C** (a), **BERMON F** (a), **AMAR T** (a), **CAILLAUD T** (a), POLZER H (b)
ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6002
(a) IRIS PHARMA, Nice, France - (b) MEDPROJECT PHARMA, Bayern, Germany

#2009-153



Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits

AMAR T (a), **CAILLAUD T** (a), **ELENA PP** (a)
Curr Eye Res. 2008; 33: 149-158
(a) IRIS PHARMA, Nice, France

#2008-152



Immunohistochemistry and in situ zymography to assess matrix metalloproteinases expression and activation by latanoprost in rat uveoscleral pathway

ELENA PP (a), **FRETON A** (a), **SPADAFORA A** (a), **GRILLO-ANTONELLI S** (a), **CIMBOLINI N** (a), **FERAILLE L** (a), LAZDUNSKI M (b)
ARVO meeting 2008; Fort Lauderdale, FL - USA. ARVO e-abstract No. 2616
(a) IRIS PHARMA, Nice, France - (b) IPMC-UMR 6097, Valbonne, France

#2008-149



Comparaison in vivo de médicaments anti-allergiques avec microscope confocal afin d'évaluer la réponse tardive à l'anaphylaxie induit chez le cobaye

FERAILLE L (a)
AOP 2007 - S85 ; Paris - France. Oral communication in French
(a) IRIS PHARMA, Nice, France

#2007-242



Netildex versus Tobradex®: ocular pharmacokinetic/pharmacodynamic after a single dose and after one-day treatment in pigmented rabbits

CIVIALE C (a), BLANCO A (a), SUDANO-ROCCARO A (a), **AMAR T** (b) MAZZONE M (a)
Invest. Ophthalmol. Vis. Sci. 2007; 48(13):4272. doi:
(a) SIFI SPA, Lavinaio-Aci San Antonio, Italy - (b) IRIS PHARMA, Nice, France

#2007-226



Ether-lipid-deficient-mice display pigmentary glaucoma features as well as abnormal retinal vasculature#2007-225

ACAR N (a), SICARD P (b), SCHNEBELEN C (a), **CIMBOLINI N** (c), IVINGS L (a), **GRILLO-ANTONELLI S** (c), ROCHETTE L (b), CREUZOT-GARCHER CP (a,d), BRETILLON L (a), JUST WW (e)

ARVO meeting 2007; Fort Lauderdale, FL - USA. Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2978. doi:

(a) INRA, Dijon, France - (b) Faculties of Medicine and Pharmacy, Dijon, France - (c) IRIS PHARMA, Nice, France - (d) University Hospital, Dijon, France - (e) Biochemie Zentrum Heidelberg (BZH), Heidelberg, Germany

Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal keratoconjunctivitis sicca (VKC)#2007-148

LAMBERT G (a), RABINOVICH-GUILATT L (a)

ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO poster No. 2301/B999 (collaboration)

(a) NOVAGALI PHARMA SA, Evry, France



Ocular tolerability of iontophoresis#2007-147

ROY P (a), **ELENA PP** (b), **VIAUD K** (b), **CAILLAUD T** (b), CALIAS P

ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5800

(a) EYEGATE Pharmaceuticals, Waltham, USA - (b) IRIS PHARMA, Nice, France

New evaluation techniques in ocular surface diseases: comparison of anti-allergic drugs using in vivo confocal microscopy for assessing late response of induced ocular anaphylaxis in the guinea pig#2007-146

FERAILLE L (a)

Oral presentation. EVER meeting 2007; Portoroz, Slovenia

(a) IRIS PHARMA, Nice, France



Update on drug delivery systems used in the anterior part of the eye: review of the new drug delivery systems for the anterior chamber#2007-145

ELENA PP (a)

Oral presentation. ESCRS meeting 2007; Stockholm, Sweden

(a) IRIS PHARMA, Nice, France



In vivo characterization of the anti-inflammatory effect of a multikinase inhibitor targeting angiogenesis and inflammation#2007-141

JENSEN L (a), HJARNAA P (a), FENSHOLDT J (a), **ELENA PP** (b), ABELL K (a), PETERSEN TK (a)

8th World Congress on Inflammation 2007; Copenhagen, Denmark. Inflamm Res. 2007; 56(suppl.3): S443, abstract P07.21

(a) LEO PHARMA, Ballerup, Denmark - (b) IRIS PHARMA, Nice, France



The role of the CROs in the ophthalmological drug development in Europe#2006-140

ELENA PP (a)

Oral presentation. ISOPT meeting 2006; Berlin, Germany

(a) IRIS PHARMA, Nice, France

Pharmacokinetics of clonidine after a single application of transscleral iontophoresis in rabbits#2006-131

CAILLAUD T (a), ROY P (b), **VIAUD K** (a), **ELENA PP** (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 5109

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

Influence of solution composition and electrode design on transscleral iontophoresis delivery of dexamethasone disodium phosphate#2006-130

ROY P (a), **VIAUD K** (b), **CAILLAUD T** (b), **ELENA PP** (b)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5110

(a) EYEGATE, Paris, France - (b) IRIS PHARMA, Nice, France

Evaluation of ocular tolerability of repetitive corneal-scleral iontophoresis in pigmented rabbits#2006-129

ELENA PP (a), ROY P (b), **VIAUD K** (a), **CAILLAUD T** (a)

ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5094

(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

Effects of dexamethasone in a rat model of choroidal neovascularization#2006-128

FERAILLE L (a), **GRILLO-ANTONELLI S** (a), **CIMBOLINI N** (a), **CAILLAUD T** (a), **ELENA PP** (a)

Ocular Anti-Angiogenesis meeting 2006; London - United Kingdom

(a) IRIS PHARMA, Nice, France



Variation of krüppel-like factors levels in mouse corneal model of angiogenesis#2005-127

CHIAMBARETTA F, DE GRAEVE F, **FERAILLE L**, NEZZAR H, MARCEAU G, DASTUGNE B, RIGAL D, **ELENA PP**, SAPIN V

ARVO meeting 2005; Fort Lauderdale, FL. Invest. Ophthalmol. Vis. Sci. 2005; 46: ARVO e-abstract No. 2609

- Variation of krüppel-like factors ARNm levels in a mouse corneal model of angiogenesis**#2005-123
 CHIAMBARETTA F, NEZZAR H, **FERAILLE L**, DE GRAEVE F, MARCEAU G, **ELENA PP**, RIGAL D, DASTUGUE B, SAPIN V
 SFO meeting 2005; Paris – France. Abstract No. 380
- PKC412 content in retina, choroid and plasma of pup mice with retinal neovascularization induced by hyperoxic stimuli**#2004-116
ELENA PP (a), **AMAR T** (a), **CAILLAUD T**(a), WONG M (b), BIZEC JC (C)
 ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4053
 (a) IRIS PHARMA, Nice, France - (b) NOVARTIS PHARMA, EAST HANOVER, USA - (C) NOVARTIS PHARMA AG, Basel, Switzerland
- PKC412 reduces retinal neovascularization induced by hypoxic stimuli in pup mice**#2004-115
CAILLAUD T (a), **AMAR T** (a), OTTLECHZ A (b), WONG M (c), LAMBROU GN (b), **ELENA PP** (a)
 ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4062
 (a) IRIS PHARMA, Nice, France - (b) NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland - (c) NOVARTIS PHARMA, East Hanover, USA
- In vivo and in vitro neurotoxicity of the human prion protein (PrP) fragment P118-135 independently of PrP expression**#2003-114
 CHABRY J, **RATSIMANOHATRA C**, SPONNE I, **ELENA PP**, VINCENT JP, PILLOT T
 J Neurosci. 2003; Jan 15; 23(2): 462-9
- Alginate acid effect on carteolol ocular pharmacokinetics in the pigmented rabbit**#2002-111
 TISSIE G, SEBASTIAN C, **ELENA PP**, DRIOT JY, TRINQUAND C
 J. Ocul. Pharmacol. Ther. 2002; 18: 65-73
- Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits**#2001-113
 YERXA BR, DOUGLASS JG, **ELENA PP**, **CAILLAUD T**, **AMAR T**, REDICK CC, PETERSON WM
 Adv. Exp. Med. Biol. 2002; 506: 261-265
- Topical ocular instillation of nitric oxide synthase inhibitors and intraocular pressure in rabbits**#2001-110
 FLEISCHHAUER JC, LIU R, **ELENA PP**, FLAMMER J, HAEFLIGER IO
 Klin. Monatsbl. Augenheilkd. 2001; 218: 351-353
- Ocular distribution of CAT-152 after a single subconjunctival injection in a pigmented rabbit model of glaucoma filtration surgery**#2001-108
ELENA PP, MCFARLANE S, GLOVER DR, **AMAR T**, **CAILLAUD T**
 ARVO meeting 2001; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2001; 42: S544, abstract No. 2915
- Effect of CO₂ pneumoperitoneum on early cellular markers of retinal ischemia in rabbits with a-chymotrypsin-induced glaucoma**#2000-234
 LENTSCHENE C (a), FREDJ-REYGRABELLET D (b), BOUAZIZ H (c), MAZOIT JX (d), NIESSEN F (a), BENHAMOU D (a)
 Surg. Endosc. 2000; 14: 1057–1961 DOI: 10.1007/s004640000257 (collaboration)
 (a) Hôpital Antoine Béchère, Clamart, France - (b) Faculté de Médecine Nice, France - (c) Hôpital Central, Nancy, France - (d) Hôpital de Bicêtre, le Kremlin Bicêtre Cedex, France
- A new long acting ophthalmic formulation of carteolol containing alginate acid**#2000-106
 SECHOY O, TISSIE G, SEBASTIAN C, MAURIN F, DRIOT JY, TRINQUANT C
 Int. J. Pharm. 2000; 207: 109-116. (collaboration)
- Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension**#2000-104
 LACHERETZ F, BARBIER A, SERRADEIL-LE GAL C, **ELENA PP**, MAFFRAND J, LE FUR G
 J. Ocul. Pharmacol. Ther. 2000; 16: 203-216
- Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits**#2000-103
 PISELLA PJ (a,b), FILLACIER K (d), **ELENA PP** (e), DEBBASCH C (b,c), BAUDOUIN C (a)
 Ophthalmic Res. 2000; 32: 3-8
 (a) Department of Ophthalmology, Ambroise Paré Hospital, APHP, Paris, France - (b) Toxicology Laboratory, University of Paris-V René Descartes, Paris, France - (c) Department of Cellular Pharmacotoxicology, XV-XX Hospital, Paris, France - (d) Department of Ophthalmology, University of Nice, France - (e) IRIS PHARMA, Nice, France
- Localisation of Venoruton in rat blood vessel after single oral administration**#2000-102
 SALLIN D, **ELENA PP**, ZIJLSTRA J
 14th World Congress of the 'Union Internationale de Phlébologie' Roma - Italy 2000

- Evaluation of a novel carteolol eye-drops with alginate acid as long action promoter**#2000-101
 TISSIE G, SEBASTIAN C, MAURIN F, SECHOY O, DRIOT JY, **ELENA PP**, TRINQUAND C
 EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 29, abstract No. 214
- Alginate acid effect on ocular distribution of carteolol after a single instillation in pigmented rabbits**#2000-100
 SEBASTIAN C, TISSIE G, DRIOT JY, **ELENA PP**, TRINQUAND C
 EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 28, abstract No. 215
- Potency and duration of action of synthetic P2Y2-receptor agonists on schirmer scores in rabbits**#2000-99
 YERXA BR, DOUGLASS JG, **ELENA PP**, **CAILLAUD T**, **AMAR T**, PETERSON WM
 (3rd International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes Maui, HI - USA) Cornea 2000; 19: S138
- Ethics committee recommendations for laboratory animals in private research in France**#2000-98
 B. VERSCHUERE B, AUTISSIER C, DEGRYSE AD, GALLIX P, GOTTI B, LAURENT J, LEINOT M, PEYCLIT I
 Laboratory Animals 2000; 34: 236-243. (collaboration)
- Benefits of a vasopressin V2 receptor antagonist, SR 121463, in the treatment of ocular hypertension in the rabbit**#1999-97
 SERRADEIL-LE GAL C, LACHERETZ F, BARBIER A, **ELENA PP**, PASCAL M, MAFFRAND JP, LE FUR G
 World Congress on Neurohypophysial Hormones. 1999; Edinburgh – UK
- INS365, a P2Y2 receptor agonist, increases schirmer scores in albino rabbits**#1999-96
 YERXA BR, **ELENA PP**, **CAILLAUD T**, **AMAR T**, EVANS R
 ARVO meeting 1999; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1999; 40: S540, abstract No. 2848
- Inflammation measurement and immunocharacterization of cell proliferation in an experimental model of proliferative vitreoretinopathy**#1998-95
 BAUDOUIN C, KHOSRAVI E, PISELLA PJ, ETTAICHE M, **ELENA PP**
 Ophthalmic Res. 1998; 30: 340-350
- The effect of pneumoperitoneum on intraocular pressure in rabbits with α -chymotrypsin-induced glaucoma**#1998-94
 LENTSCHENER C, LEVEQUE JP, MAZOIT JX, BENHAMOU D
 Anesth. Analg. 1998; 86: 1283-1288. (collaboration)
- Activity of SR121463, a selective non-peptide vasopressine V2 receptor antagonist, in a rabbit model of glaucoma**#1998-93
 LACHERETZ F, BARBIER A, SERRADEIL-LE GAL C, **ELENA PP**, MAFFRAND JP, LE FUR G
 (ISER 1998 Abstract No. 795; Paris - France) Exp. Eye Res. 1998; 67: S239
- Protective effect of nicardipine, a calcium channel blocker on electroretinogram and retinal cytoskeletal damages after ischemia-reperfusion on the rat**#1998-92
 FREDJ-REYGRABELLET D, **CAILLAUD T**, **ELENA PP**
 ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39: S993, abstract No. 4591
- Comparison of efficacy between ketotifen and olopatadine eyedrops in allergic conjunctivitis**#1998-91
ELENA PP, **AMAR T**, FETZ A, SCHOCH C
 ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39: S549, abstract No. 2531
- Ocular distribution of lomefloxacin 0.3 % after a single instillation in the infected eye of pigmented rabbits**#1997-90
ELENA PP, JAUCH A
 J. Ocul. Pharmacol. Ther. 1997; 13: 551-558
- Intraocular pressure effects of topical rilmenidine in ocular hypertensive animals and in healthy volunteers and glaucoma subjects**#1997-89
 NORDMANN JP, **ELENA PP**, VILAIN C
 ISECOPP meeting 1997 Munich – Germany, p. 12
- Analyse de l'inflammation et de la prolifération cellulaire intra-oculaires dans un modèle expérimental de prolifération vitréorétinienne**#1997-87
 PISELLA PJ, BECQUET F, **ELENA PP**, BAUDOUIN C
 Ophthalmologie (France) 1997; 11: 369-371

Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits#1997-86

TILLEUL P, DENIS P, MAIGNEN F, **ELENA PP**, NORDMANN JP, LEVERGE R, ROSTENE W
Ophthalmic Res. 1997; 29: 218-226



Retinal damage and protection after ischemic injury in the rat: a reappraisal#1997-85

ELENA PP, **CAILLAUD T**, **AMAR T**, HARITON C
ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S888, abstract No. 4151

Ocular distribution of Rescula® Eye-Drops in the pigmented rabbit after a single topical administration#1997-84

CAILLAUD T, **AMAR T**, HARITON C, **ELENA PP**
ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S815, abstract No. 3796

Rilmenidine: effect on intraocular pressure in alpha-chymotrypsin rabbits#1997-83

AMAR T, NORDMANN JP, CASTAGNE I, VILAIN C, **ELENA PP**
ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S814, abstract No. 3790

Protection induced by isopropyl unoprostone treatment after retinal ischemic injury in the rat#1997-76

MOREL-MANDRINO P, **CAILLAUD T**, **ELENA PP**, HARITON C
ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S103, abstract No. 502

Inflammation measurement and immunocharacterization of cell proliferation in experimental PVR#1996-81

BAUDOUIIN C, PISELLA PJ, **KHOSRAVI E**, ETTAICHE M, **ELENA PP**
ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S391, abstract No. 1808

Antiproliferative activity of a liposomal delivery system of mitoxantrone on rabbit subconjunctival fibroblasts in an ex-vivo model#1996-80

MAIGNEN F, TILLEUL P, BILLARDON C, XU-VAN OPSTAL WY, PELAPRAT D, **ELENA PP**, DENIS P, ROSTENE W
J. Ocul. Pharmacol. Ther. 1996; 12: 289-298

The renin-angiotensin system in the rabbit eye#1996-79

RAMIREZ M, DAVIDSON EA, LUTTENAUER L, **ELENA PP**, CUMIN F, MATHIS GA, DE GASPARO M
J. Ocul. Pharmacol. Ther. 1996; 12: 299-312



Histological and cytological retinal changes after pressure-induced ischemia in rat eye#1996-78

FREDJ-REYGRABELLET D, **TABIASCO J**, BALAS D, DENIS P, **ELENA PP**
(JERMOV 1996 Abstract No. 399; Montpellier - France) Vision Res. 1996; 36: S220

Pharmacokinetics of 0.1 % azelastine eyedrops, a histamine-H1-antagonist, with or without an induced allergic conjunctivitis#1996-77

ELENA PP, **KHOSRAVI E**, BORBE H, HERBST M, PETER G
ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S1027, abstract No. 4719

Ocular bioavailability of ganciclovir gel, an anti-herpetic formulation, after topical administration to intact or removed corneal epithelium of rabbit eyes#1996-74

KHOSRAVI E, **ELENA PP**, GOLDSCHMIDT P, LUYCKX J
ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S81, abstract No. 383

Allergic conjunctivitis and uveitis models: reappraisal with some marketed drugs#1995-73

KHOSRAVI E, **ELENA PP**, HARITON C
Inflamm. Res. 1995; 44: 47-54



Intraocular pressure effects of topical renin inhibitor CGP 38560 in normal and ocular hypertensive animals and in healthy volunteers and glaucoma subjects#1995-72

NORDMANN JP, PERCICOT CL, ELENA PP, MATHIS GA
ISECOPP meeting 1995; Geneva - Switzerland, p. 35

Lomefloxacin distribution after a single instillation in the infected eye of pigmented rabbits#1995-69

KHOSRAVI E, **ELENA PP**, JAUCH A
ISECOPP meeting 1995 Geneva - Switzerland, p. 67

Non-invasive measurement of ocular temperature by using infrared thermographic analysis in immune and non-immune allergy models#1995-68

ELENA PP, **KHOSRAVI E**, HARITON C
ISECOPP meeting 1995; Geneva - Switzerland, p. 60

- The renin angiotensin system in the rabbit eye**#1995-67
RAMIREZ M, DAVIDSON EA, **ELENA PP**, MATHIS GA, DE GASPARO M
ISECOPP meeting 1995; Geneva - Switzerland, p. 25
- Lack of cytotoxic effect of ganciclovir and acyclovir on rabbit corneal epithelial cells in vitro**#1995-66
KHOSRAVI E, ELENA PP, GOLDSCHMIDT P, BAUDOQUIN C, LUYCKX J
JERMOV meeting 1995; Montpellier - France. Vision Res. 1995; 35: S173, abstract No. P125
- Dimethindene maleate in allergic conjunctivitis: a new indication for an old drug**#1995-65
ELENA PP, KHOSRAVI E, HARITON C
ARVO meeting 1995; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1995; 36: S1014, abstract No. 4699
- Correlation between anterior chamber inflammation and proliferative vitreoretinopathy in the rabbit**#1994-64
KHOSRAVI E, BAUDOQUIN C, ELENA PP
JERMOV meeting 1994; Montpellier - France, p 240, abstract No. P192
- Central nervous system control of intraocular pressure**#1994-63
DENIS P, NORDMANN JP, **ELENA PP**, SARAUX H, and LAPALUS P
Fundam. Clin. Pharmacol. (France) 1994; 8: 230-237
- Ocular distribution of nicergoline after intravenous administration in rats**#1994-62
ELENA PP, BERTHOLOM N, KHOSRAVI E
JERMOV meeting 1994; Montpellier - France, p 173, abstract No. P12
- Topical sodium sucrose octasulphate reduces corneal lesions in a keratoconjunctivitis sicca model in the rat**#1994-61
CHIBRET H, **ELENA PP, KHOSRAVI E**, FREDJ-REYGRABELLET D
ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1693, abstract No. 2039
- Distribution of ganciclovir in the anterior uvea after topical application of 0.15 % ganciclovir gel to intact and HSV-infected eyes of rabbits**#1994-60
ELENA PP, GOLDSCHMIDT P, CHAST F, SAUVAGEON H, LUYCKX J, KHOSRAVI E
ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1682, abstract No. 1984
- Angiotensin-II antagonists reduce intraocular pressure by a combined effect on aqueous humor synthesis and outflow**#1994-58
MATHIS GA, PERCICOT C, MERMOUD A, **ELENA PP**
ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1483, abstract No. 1060
- Physiological roles of dopamine and neuropeptides in the retina**#1993-57
DENIS P, NORDMANN JP, **ELENA PP**, DUSSAILLANT M, SARAUX H, LAPALUS P
Fundam. Clin. Pharmacol. (France) 1993; 7: 293-304
- Bioequivalence between timolol maleate formulated in ophthalmic solution (Timoptol®) and in a novel gel vehicle (T-Gel)**#1993-56
ELENA PP, POLZER H, KHOSRAVI E
ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1490, abstract No. 3902
- Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed corneal epithelium**#1993-55
CHIBRET H, **ELENA PP, KHOSRAVI E**
ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1050, abstract No. 1712
- Mifepristone (RU 486): in vitro binding to glucocorticoid receptors in iris-ciliary body and in vivo effects on intraocular pressure in rabbits**#1993-54
DENIS P, **ELENA PP**, NORDMANN JP, SARRIEAU A, SARAUX H, ROSTENE W
ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 925, abstract No. 1115
- Piribédil : affinité pour les récepteurs dopaminergiques rétiniens et profil pharmacocinétique oculaire**#1993-53
LAPALUS P, DENIS P, DRICI M, FREDJ-REYGRABELLET D, **ELENA PP**
J. Neur. 1993; 240 (Suppl 1): S17-S21 
- Retinal dopaminergic receptor affinity and ocular pharmacokinetic profile of piribedil**#1992-52
LAPALUS P, DENIS P, DRICI M, FREDJ-REYGRABELLET D, **ELENA PP**
J. Neurol. 1992; 239 (Suppl 1): S17-S21 

- Ocular pharmacokinetics of trimetazidine in the pigmented rat after a single oral administration**#1992-51
ELENA PP, KHOSRAVI E, LAPALUS P, JOULIN Y, HARPEY C
 ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S55, abstract No. 184
- Effect of diclofenac sodium and diclofenac sodium SDU eyedrops on prostaglandin concentrations in aqueous humor of rabbits after extracapsular surgery**#1992-50
ELENA PP, ULRICH E, TSCHALÄR Y, LAPALUS P, ETTAICHE M, KHOSRAVI E
 ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 183
- Ocular pharmacokinetics of two preservatives, benzalkonium chloride or benzoxonium chloride, after instillation in the pigmented rabbit**#1992-49
ELENA PP, KHOSRAVI E, LAPALUS P, ULRICH E
 ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 182
- Preclinical pharmacokinetics of the 14C-labelled aldose reductase inhibitor methosorbinil (E-0722)**#1992-48
ELENA PP, KUNZ PA, LAPALUS P
 SOE meeting 1992; Brussels - Belgium, p. 188, abstract No. 737
- La radioautographie en ophtalmologie : méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ**#1991-47
DENIS P, ELENA PP, NORDMANN JP, DUSSAILLANT M, LAPALUS P, SARAUX H, ROSTENE W
 "Physiologie, Pathologie et Génétique Oculaire." CHRISTEN Y AND DROIX-LEFAIX MT ed. (Springer Verlag, Paris, 1991), 105-113
- Localisation et caractérisation radioautographiques des récepteurs β -adrénergiques oculaires dans les structures non pigmentées chez l'homme**#1991-46
LAPALUS P, ELENA PP, NORDMANN JP, LAROCHE L, SARAUX H, LAPALUS P
 Ophtalmologie (France) 1991; 5: 53-56
- Localization and characterization of substance P binding sites in rat and rabbit eyes**#1991-45
DENIS P, FARDIN V, NORDMANN JP, ELENA PP, LAROCHE L, SARAUX H, ROSTENE W
 Invest. Ophthalmol. Vis. Sci. 1991; 32: 1894-1902
- Autoradiographic characterization and localization of vasoactive intestinal peptide binding sites in albino rat and rabbit eyes**#1991-44
DENIS P, DUSSAILLANT M, NORDMANN JP, ELENA PP, SARAUX H, ROSTENE W
 Exp. Eye Res. 1991; 52: 357-366
- Autoradiographic localization of β -adrenergic binding sites in human retinal blood vessels**#1991-43
DENIS P, ELENA PP, LAPALUS P
 Chibret Int. J. 1991; 7: 14-19
- Distribution rétinienne des sites récepteurs dopaminergiques rétinien chez l'homme. Hypothèses fonctionnelles sur le rôle de la dopamine dans la vision**#1991-42
DENIS P, NORDMANN JP, ELENA PP, LAPALUS P
 (Dopamine, Fonctions Cérébrales et Neurosensorielles; Budapest - Hungary 1991) Euthérapie
- Autoradiographic localization of D1 and D2 dopamine binding sites in the human retina**#1990-41
DENIS P, ELENA PP, NORDMANN JP, SARAUX H, LAPALUS P
 Neurosci. Lett. 1990; 116: 81-86
- β -adrenergic binding sites in the human eye: an autoradiographic study**#1990-40
ELENA PP, DENIS P, KOSINA-BOIX M, SARAUX H, LAPALUS P
 J. Ocul. Pharmacol. 1990; 6: 143-149
- Localisation et caractérisation autoradiographiques de sites de liaison oculaires du VIP (Vasoactive Intestinal Peptide) chez le rat et le lapin albinos**#1990-39
DENIS P, DUSSAILLANT M, ELENA PP, NORDMANN JP, ROSTENE W, LAROCHE L
 Ophtalmologie (France) 1990; 4: 30-32
- Cytotoxicity studies in ophthalmology**#1990-38
LAPALUS P, ETTAICHE M, FREDJ-REYGRABELLET D, JAMBOU D, ELENA PP
 Lens Eye Toxic Res. 1990; 7: 231-242
- Ocular pharmacokinetics of ganciclovir gel after a single administration**#1990-37
LAPALUS P, ETTAICHE M, LUYCKX J, ELENA PP
 AER meeting 1990; Bad Honnef - Germany, p 58, abstract No. 94

Hymecel pharmacokinetics after a single intracameral injection in phakic and aphakic eyes of pigmented rabbits#1990-36

ELENA PP, LAPALUS P, FREDJ-REYGROBELLET D, ETTAICHE M, ULRICH E
AER meeting 1990; Bad Honnef - Germany, p 25, abstract No. 6

Specific receptors to vasculotropin in the eye#1990-35

MOUKADIRI H, DENIS P, **ELENA PP**, ROSTENE W, PLOUET J
AER meeting 1990; Bad Honnef - Germany, p 24, abstract No. 4

Localization and characterization of receptors in human and animal eyes by "in vitro" autoradiography#1990-34

ELENA PP, DENIS P, FREDJ-REYGROBELLET D, ROSTENE W, LAPALUS P
ISER meeting 1990; Helsinki - Finland, p 228, abstract No. 803

Autoradiographic localisation of insuling binding sites in the human eye#1990-33

DENIS P, **ELENA PP**, LE MARCHAND-BRUSTEL Y, NORDMANN JP, LAPALUS P, SARAUX H
ISER meeting 1990; Helsinki - Finland, p 114, abstract No. 384

Retinal dopaminergic receptors and distribution of piribedil#1990-32

LAPALUS P, **ELENA PP**, FREDJ-REYGROBELLET D, DENIS P
ENS meeting 1990; Brighton - UK

Localisation et caractérisation radioautographiques des récepteurs β -adrénergiques oculaires dans les structures non pigmentées chez l'homme#1990-31

DENIS P, **ELENA PP**, NORDMANN JP, SARAUX H, LAPALUS P
SFO meeting 1990; Paris - France

La radioautographie en ophtalmologie : méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ#1990-30

DENIS P, **ELENA PP**, NORDMANN JP, LAPALUS P, SARAUX H
Séminaires Ophtalmologiques IPSEN, Royaumont - France 1990

Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialized and intact rabbit eye#1989-29

FREDJ-REYGROBELLET D, **ELENA PP**, MOENNER M, BAUDOUIN C, ETTAICHE M, BARRITAU D, LAPALUS P
Curr. Eye Res. 1989; 8: 1141-1152

Localisation autoradiographique des récepteurs dopaminergiques réiniens chez l'homme. Implications fonctionnelles#1989-28

DENIS P, NORDMANN JP, **ELENA PP**, LAROCHE L, LAPALUS P
Bull. Soc. Ophtalmol. Fr. (France) 1989; 89: 807-810

Récepteurs béta-adrenergiques vasculaires réiniens chez l'homme#1989-27

DENIS P, **ELENA PP**
Ophtalmologie (France) 1989; 3: 62-64



Dopamine receptors in rabbit and rat eye: characterization and localization of DA1 and DA2 binding sites#1989-26

ELENA PP, DENIS P, KOSINA-BOIX M, LAPALUS P
Curr. Eye Res. 1989; 8: 75-83

Alpha2-adrenergic receptors in rat and rabbit eye: a tritium-sensitive film autoradiography#1989-25

ELENA PP, KOSINA-BOIX M, DENIS P, MOULIN G, LAPALUS P
Ophthalmic Res. 1989; 21: 309-314



Localisation of angiotensin-converting enzyme (ACE) in rat ciliary process by autoradiography and immunocytochemistry#1989-24

LALIBERTE F, **ELENA PP**, LALIBERTE MF, LAPALUS P, CHEVILLARD C
AER meeting 1989; Montpellier - France, Doc. Ophthalmol. 1990; 76: 194-195, abstract No. 167

Beta-adrenergic receptors in human eye sections#1989-23

ELENA PP, DENIS P, LAROCHE L, and LAPALUS P
AER meeting 1989; Montpellier - France, Doc. Ophthalmol. 1990; 76: 194, abstract No. 166

Autoradiographic localization of vasoactive intestinal peptide binding sites in albino rabbit and rat eye#1989-22

DENIS P, DUSSAILLANT M, NORDMANN JP, **ELENA PP**, ROSTENE W, SARAUX H
AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 159-160, abstract No. 104

- Autoradiographic localisation of insulin receptors in the human eye**#1989-21
ELENA PP, DENIS P, LE MARCHAND-BRUSTEL Y, LAPALUS P
 AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 158-159, abstract No. 102
- Pharmacokinetics of topically-administered aldose reductase inhibitor (E-0722) on pigmented rabbit eye**#1989-20
 LAPALUS P, FREDJ-REYGROBELLET D, **ELENA PP**
 AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 129-130, abstract No. 45
- Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialised and intact rabbit eye**#1989-19
 FREDJ-REYGROBELLET D, **ELENA PP**, MOENNER M, BAUDOUIN C, ETTAICHE M, BARRITAU D, LAPALUS P
 AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 111, abstract No. 13
- Piribedil and retinal dopaminergic binding sites**#1989-18
 LAPALUS P, **ELENA PP**, DENIS P, FREDJ-REYGROBELLET D
 World Congress of Neurology 1989, New Dehli - India
- Localisation autoradiographique des récepteurs dopaminergiques réiniens chez l'homme. Implications fonctionnelles**#1989-17
 DENIS P, NORDMANN JP, **ELENA PP**, LAROCHE L, LAPALUS P
 SFO meeting 1989, Paris - France
- Neurotransmitters and intraocular pressure**#1989-16
 LAPALUS P, **ELENA PP**
 Fundam. Clin. Pharmacol. (France) 1988; 2: 305-325
- Autoradiographic localization of beta-adrenergic binding sites in human blood retinal vessels**#1988-15
ELENA PP, DENIS P, LAPALUS P
 ISER meeting 1988, San Francisco, CA - USA
- Autoradiographic characterization of D-1 and D-2 receptors in rat, rabbit and human eyes**#1988-14
ELENA PP, DENIS P, LAPALUS P
 ISER meeting 1988, San Francisco, CA - USA
- Autoradiographic localization of β -adrenergic receptors in rabbit eye**#1987-13
ELENA PP (a), KOSINA-BOIX M (b), MOULIN G (a), LAPALUS P (b)
 Invest. Ophthalmol. Vis. Sci. 1987; 28: 1436-1441
 (a) Laboratoires DULCIS ALLERGAN, Monaco - (b) the Laboratoire de Pharmacologie Faculte de Medecine, Nice, France 
- Dopamine DA1 receptors in the eye: characterization and localization of 125I-SCH 23982 binding sites**#1987-12
ELENA PP, KOSINA-BOIX M, LAPALUS P
 AER meeting 1987, Leuven - Belgium
- Effects of a new anti-allergic agent: the magnesium salt of N-Acetyl-Aspartyl-Glutamic Acid on experimental allergic inflammation of the rabbit eye**#1986-11
 LAPALUS P, MOULIN G, BAYER V, FREDJ-REYGROBELLET D, **ELENA PP**
 Curr. Eye Res. 1986; 5: 517-522
- Monoclonal antibodies to human amnion recognize different components of the rabbit eye**#1986-10
 HSI BL, FREDJ-REYGROBELLET D, YEH CJG, **ELENA PP**, MOULIN G, LAPALUS P
 Invest. Ophthalmol. Vis. Sci. 1986; 27: 620-622 
- Système alpha-adrénergique et pression intra-oculaire**#1986-9
 LAPALUS P, **ELENA PP**
 Rencontres Internationales de Chimie Thérapeutique, Clermont-Ferrand - France 1986
- Autoradiographic localization of β -adrenergic receptors in rabbit eye**#1986-8
ELENA PP, KOSINA-BOIX M, MOULIN G, LAPALUS P
 AER meeting 1986, Oxford - UK
- Embryological studies of rabbit eye by using monoclonal antibodies**#1985-7
 FREDJ-REYGROBELLET D, HSI BL, MOULIN G, YEH CJG, **ELENA PP**, and LAPALUS P
 AER meeting 1985, Leyzin - Switzerland, p 61 abstract No. 73

Alpha-adrenoceptors in rabbit iris-ciliary-body (ICB) membranes: characterization and localization with 3H-clonidine#1985-6

ELENA PP, PALTRINIERI P, MOULIN G, FREDJ-REYGRABELLET D, LAPALUS P
AER meeting 1985, Leyzin - Switzerland, p 5

Pharmacological characteristics of β -adrenergic-sensitive adenylate cyclase in non-pigmented and pigmented cells of bovine ciliary process

ELENA PP, FREDJ-REYGRABELLET D, MOULIN G, LAPALUS P
Curr. Eye Res. 1984; 3: 1383-1389

.....#1984-5

Characterization of β -adrenergic receptors in bovine pigmented ciliary processes

ELENA PP, MOULIN G, LAPALUS P
Curr. Eye Res. 1984; 3: 743-750

.....#1984-4

Etude cinétique d'un anti-allergique, le 14C-T86 en instillation chez le lapin albinos

LAPALUS P, MOULIN G, BAYER V, **ELENA PP**, NICOLAS C, LAPALUS F
J. Biophys. Med. Nucl. 1984; 8: 195-198

.....#1984-3

Etude cinétique d'un anti-allergique, le 14C-T86, en instillation chez le lapin albinos

LAPALUS P, MOULIN G, BAYER V, **ELENA PP**, NICOLAS C, LAPALUS F
Congrès de Médecine Nucléaire de Langue Française, Nice - France 1984

.....#1984-2

Adenylate cyclase activity in non-pigmented (NPE) and in pigmented (PE) cells of bovine ciliary process#1984-1

ELENA PP, FREDJ-REYGRABELLET D, MOULIN G, LAPALUS P
ISER meeting 1984, Alicante - Spain, p 95

Wound healing of different epithelia in albino rabbit eye anterior segment

FREDJ-REYGRABELLET D, MOULIN G, **ELENA PP**, LAPALUS P
ISER meeting 1984, Alicante - Spain, p.95

.....#1984-232

ABBREVIATIONS

ARVO	A ssociation for R esearch in V ision and O phthalmology
ATERET	A ssociation T unisienne d' E tude et de R echerche sur les E léments T race
ECLSO	E uropean C ontact L ens S ociety of O phthalmologists
EVER	E uropean V ision and E ye R esearch
IGS	I nternational G laucoma S ymposium
ISECOPP	I nternational S ymposium on E xperimental and C linical O cular P harmacology and P harmaceuticals
ISOPT	I nternational S ymposium on O cular P harmacology and T herapeutics
MCLOSA	M edical C ontact L ens and O cular S urface A ssociation
SAFIR	S ociété de l' A ssociation F rançaise des I mplants et de la chirurgie R éfractive
SFERETE	S ociété F rancophone d' E tude et de R echerche sur les E léments T races T oxiques et E ssentiels
SFO	S ociété F rançaise d' O phthalmologie
SFVB	S ociété F rancophone V itamines et B iofacteurs